were collected and analyzed. The data of laboratory examinations, including peripheral lymphocyte subsets, were analyzed and compared between severe and non-severe patients.
Introduction
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that first emerged in Wuhan in December 2019, has rapidly spread throughout China in the past two months. [1, 2] Considering the ongoing outbreak in China and fast worldwide spread of coronavirus disease 2019 (COVID- 19) , infected by SARS-CoV-2, it has led to the declaration of Public Health Emergency of International Concern by the World Health Organization (WHO) on 30 January 2020.
[3] As of Feb 16, 2020, a total of 58182 laboratory-confirmed cases, has been identified in China (primarily in Wuhan), with 1696 fatal cases, according to the data from Chinese government official reports. [2] It has been reported that the COVID-19 was more likely to occur in older men with comorbidities [4] [5] [6] , who have weaker immune functions. As a new type of highly contagious disease in human, the pathophysiology of unusually high pathogenicity for COVID-19 has not been completely understood yet. Several studies have shown that increased amounts of proinflammatory cytokines in serum were associated with pulmonary inflammation and extensive lung damage in SARS [7] and MERS-CoV infection [8] , and recently in COVID-19 [5] . However, little is known about lymphocyte subsets and the immune response of patients with COVID-19.
This retrospective, single-center study aimed to analyze the expression of infection related biomarkers, inflammatory cytokines and lymphocyte subsets by flow cytometry in laboratory-confirmed cases, and compare the difference between severe cases and non-severe ones. 7 
Methods

Study design and participants
We retrospectively recruited totally 452 patients with COVID-19 from January 10 to February 12, 2020, at Tongji hospital, the largest comprehensive medical treatment center of the central China and "the specific hospital for the treatment of severe patients with COVID- 19 in Wuhan" designated by the government. The study was performed in accordance with Tongji Hospital Ethics Committee (IRB ID: TJ-C20200121). Written informed consent was waived by the Ethics Commission of the designated hospital for emerging infectious disease.
The severity of COVID-19 was judged according to the Fifth Revised Trial Version of the Novel Coronavirus Pneumonia Diagnosis and Treatment Guidance. [9] Those who met the criterion as follows were defined as severe-type: 1. Respiratory distress with the respiratory rate over 30 per minute; 2. Oxygen saturation ≤ 93% in the resting state; 3. Arterial blood oxygen partial pressure (PaO2) / oxygen concentration (FiO2) ≤300mmHg.
Data Collection
Data including demographic data, medical history, symptoms, signs, and laboratory findings were collected from patients' medical record. Laboratory results included blood routine, lymphocyte subsets, infection-related biomarkers, inflammatory cytokines, immunoglobulins and complement proteins. The total number of lymphocytes in peripheral blood was counted by hemocytometer. Lymphocyte subsets percentage were analyzed with FACSCanto flow cytometer for those COVID-19 patients on admission. [10] The absolute numbers of different lymphocyte subsets were calculated by multiplying the percentages with total lymphocyte count. PMA/ionomycin-stimulated lymphocyte function assay was performed as described previously. [11] The percentages of IFN-γ positive cells in different cell subsets were defined as the function of them. The data were reviewed by a trained team of physicians in Tongji Hospital. A cycle threshold value (Ct-value) ≤ 37 was defined as a positive test, which was based on the recommendation by the National Institute for Viral Disease Control and Prevention (China).
Real-Time Reverse Transcription Polymerase Chain Reaction Assay
Statistical Analysis
We described the categorical variables as frequency rates and percentages, and continuous variables as mean and standard deviation (SD), median and interquartile range (IQR) values.
Independent group t tests were used for the comparison of means for continuous variables that were normally distributed; conversely, the Mann-Whitney U test was used for continuous variables not normally distributed. Proportions for categorical variables were compared using the χ2 test. All statistical analyses were performed using SPSS (Statistical Package for the Social Sciences) version 20.0 software (SPSS Inc.). Two-sided P-values of less than 0.05 were considered statistically significant.
Results
Demographic and clinical characteristics of patients infected with COVID-19
By February 12, 2020, 452 consecutive patients with COVID-19 on admission to hospitalization at Tongji Hospital were recruited in this study, 286 (63.3%) of whom were clinically diagnosed as severe infection. In total, the median age was 58 years (IQR, 47-67; range, 22-95 years), and 235 (52.0%) were men. Compared with non-severe patients, severe patients were significantly older (median age, 61 years [IQR, 51-69] vs 53 years [IQR, 41-62]; P < 0.001). The proportion of men in the severe group (54.2% men) had no significant difference with the non-severe group. Of the 452 patients with COVID-19, 201 (44.0%) patients had chronic diseases (i.e., hypertension, diabetes, chronic obstructive pulmonary disease), and a higher percentage in the severe cases (146[51.0%]) than the mild cases (55[33.1%]). And those severe patients were significantly more likely to have concomitant hypertension and cardiovascular diseases (36.7% vs 18.1%; P < 0.001; 8.4% vs 1.8%; P = 0.004; respectively). The most common symptoms were fever (92.6%), shortness of breath (50.8%), expectoration (41.4%), fatigue (46.4%), dry cough (33.3%) and myalgia (21.4%).
Moreover, severe patients were significantly more likely to have short of breath and fatigue (58.4% vs 39.2%; P < 0.001; 51.4% vs 39.2%; P = 0.014; respectively) than non-severe patients. Table 2 presents the laboratory findings in patients with COVID-19. Among 452 patients who underwent laboratory examinations on admission, most of them tended to have lymphopenia, higher infection-related biomarkers (i.e. procalcitonin, erythrocyte sedimentation rate, serum ferritin, and C-reactive protein) and several elevated inflammatory cytokines (i.e. tumor necrosis factor (TNF)-α, interleukin (IL)-2R and IL-6), and there were numerous differences in blood cell counts and infection related biomarkers between severe group and non-severe group. Severe cases had higher leukocyte (5.6 vs 4.9 ×10⁹ ; P < 0.001) and neutrophil (4.3 vs 3.2 ×10⁹ ; P < 0.001) counts, lower lymphocytes counts (0.8 vs 1.0 ×10⁹ ; P < 0.001), higher neutrophil-to-lymphocyte ratio (NLR) (5.5 vs 3.2; P < 0.001) as well as lower percentages of monocytes (6. pg/mL; P = 0.037). Immunoglobulins (IgA, IgG and IgM) and complement proteins (C3 and C4) in patients with COVID-19 were within normal range. There were no significant differences in the levels of IgA, IgG, and complement proteins C3 or C4 between the mild and severe groups, while IgM slightly decreased in severe ones.
Blood cell counts, infection related biomarkers, inflammatory cytokines, immunoglobulins and complement proteins in patients with COVID-19
Lymphocyte subset analysis in patients with COVID-19
Lymphocyte subsets were analyzed in 44 patients with COVID-19 on admission (Table 3 ).
The total number of B cells, T cells and NK cells significantly decreased in patients with
COVID-19 (852.9 /uL), and more evident in the severe cases (743.6 vs 1020.1 /uL; P = 0.032) compared to the non-severe group. The mean values of the three main subsets of lymphocytes were generally decreased in patients with COVID-19, as T cells and NK cells below normal levels, and B cells within the lower level of normal range. T cells were shown to be more affected by SARS-CoV-2 as T cell count was nearly half the lower reference limit, and tend to be more hampered in severe cases (461.6 vs 663.8 /uL; P = 0.027) when compared with non-severe group.
The function of CD4+, CD8+ T cells, and NK cells, as indicated by PMA/Ionomycin stimulated IFN-γ positive cells in these three subsets, was within normal range. And no significant difference was found between severe cases and non-severe ones.
We further analyzed different subsets of T cells. Both helper T cells (CD3+CD4+) and
suppressor T cells (CD3+CD8+) in patients with COVID-19 were below normal levels, and the decline of helper T cells was more pronounced in severe cases (285.1 vs 420.5 /uL; P = 0.027). Similar tendency was also shown in the decline of suppressor T cells, although no 
Discussion
We reported here dysregulated immune system in a cohort of 452 patients with laboratory confirmed COVID-19 in Wuhan, China. Totally, increase of NLR, and T lymphopenia-in particular, decrease of CD4+ T cells-were common among patients with COVID-19, and more evident in the severe cases, but no significant change in the number of CD8+ cells and B cells. Based on these data, we suggested that COVID-19 might damage lymphocytes, especially T lymphocytes, and the immune system was impaired during the period of disease.
In the cohort, we observed that 44.0% of patients had at least one underlying disorder (i.e., hypertension, diabetes, chronic obstructive pulmonary disease), and a higher percentage of hypertension and cardiovascular disease in the severe cases than the mild individuals, in 13 consistent with those reports [5, 12] , suggested that COVID-19 is more likely to infect those elder men with chronic comorbidities due to weaker immune functions.
In terms of laboratory tests, we noted that most of infected patients presented lymphopenia and elevated levels of infection-related biomarkers, More interestingly, a higher number of neutrophils and a lower number of lymphocytes, ie, the increase of neutrophil-to-lymphocyte ratio (NLR), were found in the severe group with COVID-19 compared to the mild group.
NLR, a well-known marker of systemic inflammation and infection, has been studied as a predictor of bacterial infection, included pneumonia [13] [14] [15] . The increase of NLR in our study, consistent with the findings from Wang et al that several patients with COVID-19 had a rising neutrophil count and a falling lymphocyte count during the severe phase [12] , indicated that serious disturbance in internal environment and potential critical condition in those severe infected cases.
Higher serum levels of pro-inflammatory cytokines (TNF-α, IL-1 and IL-6) and chemokines (IL-8) were found in patients with severe COVID-19 compared to individuals with mild disease, similar to the results in SARS and MERS [7, 16] . Cytokines and chemokines have been thought to play an important role in immunity and immunopathology during virus infections [16, 17] . Although there is no direct evidence for the involvement of proinflammatory cytokines and chemokines in lung pathology during COVID-19, the change of laboratory parameters, including elevated serum cytokine, chemokine levels, and increased NLR in infected patients were correlated with the severity of the disease and adverse outcome, suggesting a possible role for hyper-inflammatory responses in COVID-19 pathogenesis.
Virus-induced direct cytopathic effects and viral evasion of host immune responses are believed to play major roles in disease severity [16, 17] . A rapid and well-coordinated innate immune response is the first line of defense against viral infections, however, when immune response is dysregulated, it will result in an excessive inflammation, even cause death [18] . In our study, we demonstrated pronounced lymphopenia and low counts of CD3+ cells and CD4+ cells in COVID-19 cases. The differentiation of naïve CD4+ T-cells into effector and memory subsets is one of the most fundamental facets of T-cell-mediated immunity [19] . And the balance between the naïve and memory CD4+ T cells is crucial for maintaining an efficient immune response. Our results of lymphocyte subsets with higher naïve CD4+ T-cell subpopulations and smaller percentages of memory cells, higher naïve: memory ratio, in severe cases indicated that immune system in severe infection subgroup was impaired more severely. In addition, the decrease of regulatory T cells, especially induced regulatory T cells which have a key role in restraining allergic inflammation at mucosal surfaces, was demonstrated in those infected patients, especially in the severe group. Furthermore, similar tendency was also presented in naïve regulatory T cells, which underlie the control of systemic and tissue specific autoimmunity. It has been shown that T cells, especially CD4+ and CD8+ T cells, play an important role in weakening or dampening overactive innate immune responses during viral infection [18] . Whereas, regulatory T cells, a subset of T helper cells, play a crucial role in negatively regulating the activation, proliferation, and effector functions of a wide range of immune cells for the maintenance of self-tolerance and immune homeostasis [20, 21] . Given that higher expression of proinflammatory cytokines and chemokines in COVID-19 patients, especially in the severe cases, the consumption of CD4+ and CD8+ T cells, and the decrease of regulatory T cells, presented in our study, might result in aggravated inflammatory responses, the production of cytokine storm and make damaged tissue worse. Although not so sure, correlative evidence from those severe patients with lower number of lymphocytes suggested a role for dysregulated immune responses in COVID-19 pathogenesis. 15 There were several limitations in our study which might make some potential bias. First, it was a retrospective, single center and small sample study of patients admitted to hospital; standardized data for a larger cohort would be better to assess the temporal change of immune response after infection with COVID-19. Second, those patients with COVID-19 who have bacterial co-infection or superinfection might affect the results of immune response. Most of them presented the increase of NLR and procalcitonin, and more evident in severe cases, indicated potential bacterial co-infection due to dysregulated immune system.
Despite that, our study demonstrated several novel information about dysregulated immune response in COVID-19 patients that SARS-CoV-2 might mainly act on lymphocytes, especially T lymphocytes, induce a cytokine storm in the body, and generate a series of immune responses to damage the corresponding organs; thus, surveillance of NLR and lymphocyte subsets is helpful in the early screening of critical illness, diagnosis and treatment of COVID-19.
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Inflammatory cytokines
Tumor necrosis factor-α, pg/mL 0.0-8.1 8.6 (6.9-10.9) 8.4 (6.9-10.4) 8.7 (7.1-11.6) 0.037
Interleukin-1β, pg/mL 0.0-5. 
